Related Experiment Videos
[Indications for bone marrow graft in severe hemoglobinopathies]
1Unité d'Hémato-Oncologie, Hôpital Universitaire des Enfants Reine Fabiola, Bruxelles.
Revue Medicale De Bruxelles
|June 1, 1992
Summary
Allogenic bone marrow transplantation (ABMT) offers a cure for severe sickle cell anemia and major beta-thalassemia. It is recommended for severe sickle cell cases and young beta-thalassemia patients with a matched family donor.
Area of Science:
- Hematology
- Transplantation Medicine
- Genetics
Context:
- Sickle cell anemia and major beta-thalassemia are severe inherited blood disorders.
- Allogenic bone marrow transplantation (ABMT) is a potential curative treatment.
Purpose:
- To outline the role and indications of ABMT for sickle cell anemia and major beta-thalassemia.
- To define patient selection criteria for successful transplantation.
Summary:
- ABMT is the sole curative option for sickle cell anemia and major beta-thalassemia.
- For sickle cell anemia, ABMT is considered for severe clinical manifestations.
- For major beta-thalassemia, ABMT is indicated in young patients with an HLA-identical familial donor.
Impact:
- ABMT provides a pathway to cure for patients with life-threatening hemoglobinopathies.
- Establishes clear guidelines for the application of ABMT in specific patient populations.
- Highlights the importance of donor matching and patient age in transplantation success.